Overview

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Institute of Pharmaceutical Research Co., Ltd
Treatments:
Clopidogrel